BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chen JF, Wu ZQ, Liu HS, Yan S, Wang YX, Xing M, Song XQ, Ding SY. Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China. World J Gastroenterol 2024; 30(10): 1346-1357 [PMID: 38596503 DOI: 10.3748/wjg.v30.i10.1346]
URL: https://www.wjgnet.com/1949-8470/full/v30/i10/1346.htm
Number Citing Articles
1
Tsvetelina Velikova, Milena Gulinac. Novel insights into autophagy in gastrointestinal pathologies, mechanisms in metabolic dysfunction-associated fatty liver disease and acute liver failureWorld Journal of Gastroenterology 2024; 30(27): 3273-3277 doi: 10.3748/wjg.v30.i27.3273
2
Wen-Xiu Liu, Lei Liu. Predictive value of serum alanine aminotransferase for fatty liver associated with metabolic dysfunctionWorld Journal of Hepatology 2024; 16(7): 990-994 doi: 10.4254/wjh.v16.i7.990
3
Yanyan Xuan, Dingting Wu, Qin Zhang, Zhiqiang Yu, Jingbo Yu, Dongdong Zhou. Elevated ALT/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United StatesFrontiers in Endocrinology 2024; 15 doi: 10.3389/fendo.2024.1457598
4
Yanyan Tian, Yuhao Zhou, Wang Liao, Jiayue Xia, Qiaosheng Hu, Qing Zhao, Rui Zhang, Guiju Sun, Ligang Yang, Lihua Li. Flaxseed powder supplementation in non-alcoholic fatty liver disease: a randomized controlled clinical trialFood & Function 2025; 16(4): 1389 doi: 10.1039/D4FO05847J
5
Patrizia Burra, Calogero Cammà, Pietro Invernizzi, Fabio Marra, Maurizio Pompili. Does the hepatologist still need to rely on aminotransferases in clinical practice? A reappraisal of the role of a classic biomarker in the diagnosis and clinical management of chronic liver diseasesAnnals of Hepatology 2025; 30(1): 101900 doi: 10.1016/j.aohep.2025.101900
6
Di Wang, Bing-Yan Zhou, Lei Xiang, Xu-Yong Chen, Jie-Xiong Feng. Alanine aminotransferase as a risk marker for new-onset metabolic dysfunction-associated fatty liver diseaseWorld Journal of Gastroenterology 2024; 30(25): 3132-3139 doi: 10.3748/wjg.v30.i25.3132
7
Terence N Moyana. Metabolic dysfunction-associated steatotic liver disease: The question of long-term high-normal alanine aminotransferase as a screening testWorld Journal of Gastroenterology 2024; 30(42): 4576-4582 doi: 10.3748/wjg.v30.i42.4576
8
Qihuan Yao, Guozhong Chen. Association of biochemical indicators with multimorbidity in 19,624 older adult individuals with chronic diseases: a study from Jindong District, Jinhua City, ChinaFrontiers in Public Health 2025; 13 doi: 10.3389/fpubh.2025.1472415
9
Lívia da C. Agostini, Renata B. M. e Silva, Nayara N. T. Silva, Ana Cláudia F. Lopes, Vanessa de A. Belo, Wendel Coura-Vital, Luiz Fernando de M. Teixeira, Angélica A. Lima, Glenda Nicioli da Silva. The G allele of the rs4344 polymorphism of the angiotensin-converting enzyme gene is associated with alanine aminotransferase (ALT) and gamma glutamyl transferase (GGT) in Brazilian hypertensive patientsMolecular Biology Reports 2025; 52(1) doi: 10.1007/s11033-025-10386-6
10
Amedeo Lonardo. Alanine aminotransferase predicts incident steatotic liver disease of metabolic etiology: Long life to the old biomarker!World Journal of Gastroenterology 2024; 30(24): 3016-3021 doi: 10.3748/wjg.v30.i24.3016
11
Chen-Xiao Huang, Xiao-Dong Zhou, Calvin Q Pan, Ming-Hua Zheng. Screening for metabolic dysfunction-associated fatty liver disease: Time to discard the emperor’s clothes of normal liver enzymes?World Journal of Gastroenterology 2024; 30(22): 2839-2842 doi: 10.3748/wjg.v30.i22.2839
12
Giovanna McGinty, Robert Przemioslo. Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implicationsWorld Journal of Gastroenterology 2024; 30(27): 3264-3267 doi: 10.3748/wjg.v30.i27.3264